FDA Ruling on Statin Therapy

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
In this video, David Dichek, MD, of the University of Washington Medical Center, discusses an FDA warning regarding the potential for cognitive problems and elevated blood sugar associated with taking statins. He also discusses how to address concerns that patients may have about taking statins in light of the waning.

Related Articles
The vast majority of patients with chronic kidney disease are recommended to receive statins under current cholesterol management guidelines, but half of those patients are not taking the drugs.
Patients with chronic cardiovascular disease who receive automated reminders for their prescription blood pressure and cholesterol medications are more likely to refill those drugs.
A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
Latest Issues
$auto_registration$